Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C. A case report.
A 57-year-old woman with chronic hepatitis C was treated with alpha-2b interferon (IFN). Forty-five days after the initiation of IFN therapy, she developed cardiogenic shock. Acute perimyocarditis as a cause of cardiogenic shock was clinically suspected by the findings of complete atrioventricular block, regional wall motion abnormality and pericardial effusion. Since IFN therapy may induce cardiogenic shock in some patients, it is important to carefully monitor patients under treatment with IFN for abnormal cardiac signs.
Teragawa
H
H
Department of Internal Medicine, Onomichi General Hospital, Hiroshima, Japan.
Hondo
T
T
Amano
H
H
Watanabe
H
H
Ohe
H
H
Hattori
N
N
Watanabe
Y
Y
Hino
F
F
Ohbayashi
M
M
D000208:Acute Disease; D005260:Female; D006327:Heart Block / Q000209:etiology; D006526:Hepatitis C / Q000628:therapy* / Q000635:transmission; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009200:Myocardial Contraction; D009205:Myocarditis / Q000000981:diagnostic imaging / Q000209:etiology; D010490:Pericardial Effusion / Q000000981:diagnostic imaging / Q000209:etiology; D011994:Recombinant Proteins; D012770:Shock, Cardiogenic / Q000000981:diagnostic imaging / Q000209:etiology*; D065227:Transfusion Reaction; D014463:Ultrasonography
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins